29 results on '"Aleman, B.M."'
Search Results
2. Prognosis of acute coronary syndromes after radiotherapy for breast cancer
- Author
-
Boekel, N.B., Boekel, L.Y., Buddeke, J., Jacobse, J.N., Schaapveld, M. (Michael), Hooning, M.J. (Maartje), Seynaeve, C.M. (Caroline), Baaijens, M. (Margreet), Sonke, GS, Rutgers, EJ, Russell, N.S. (Nicola), Maas, A. (Arne), Vaartjes, I. (Ilonca), Aleman, B.M., Leeuwen, F.E. (Flora) van, Boekel, N.B., Boekel, L.Y., Buddeke, J., Jacobse, J.N., Schaapveld, M. (Michael), Hooning, M.J. (Maartje), Seynaeve, C.M. (Caroline), Baaijens, M. (Margreet), Sonke, GS, Rutgers, EJ, Russell, N.S. (Nicola), Maas, A. (Arne), Vaartjes, I. (Ilonca), Aleman, B.M., and Leeuwen, F.E. (Flora) van
- Abstract
Background and purpose: Breast cancer patients treated with radiotherapy are at increased risk of subsequent acute coronary syndromes (ACS). We aimed to study if radiotherapy also influences the prognosis of these ACS. Materials and methods: We included all 398 patients diagnosed with ACS following radiotherapy from our hospital-based cohort of early breast cancer patients aged <71 years, treated 1970–2009. Cardiovascular disease incidence and cause of death were acquired through questionnaires to general practitioners and cardiologists. Internal mammary chain (IMC) irradiation delivers the highest heart doses in breast cancer radiotherapy. Hence, we compared ACS prognosis between patients treated with/without IMC-irradiation. ACS prognosis was assessed through cardiac death, death due to ACS and cardiovascular disease incidence, using multivariable Cox proportional hazard models and by estimating cumulative incidence. Results: In total, 62% of patients with ACS had received IMC-irradiation and 38% did not (median age at ACS diagnosis, 67 years). Median time between breast cancer and ACS was 15 years. After ACS, ten-year cumulative risk of cardiac death was 35% for patients wh
- Published
- 2020
- Full Text
- View/download PDF
3. Cardiovascular disease after treatment for Hodgkin's lymphoma
- Author
-
Maraldo, M.V., Giusti, F., Vogelius, I.R., Lundemann, M., Kaaij, M.A. van der, Ramadan, S., Meulemans, B., Henry-Amar, M., Aleman, B.M., Raemaekers, J.M.M., Meijnders, P., Moser, E.C., Kluin-Nelemans, H.C., Feugier, P., Casasnovas, O., Fortpied, C., Specht, L., Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), Department of Oncology, Rigshospitalet, Copenhagen University Hospital, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Department of Internal Medicine and Institure for Cardiovascular Research-Vrije Universiteit, VU University Medical Center [Amsterdam], National Cancer Institute, Cairo University, Egypt, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital, Department of Haematology, Radboud University Medical Center [Nijmegen], Middelheim Hospital, Champalimaud Clinical Center, University of Groningen [Groningen], Nutrition-Génétique et Exposition aux Risques Environnementaux (NGERE), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service d'Hématologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Rigshospitalet Research Committee, the EORTC Cancer Research Fund, and the Sally Snowman Survivorship Fellowship., EORTC Lymphoma Grp, Internal medicine, and CCA - Innovative therapy
- Subjects
Male ,Heart disease ,[SDV]Life Sciences [q-bio] ,medicine.medical_treatment ,COMBINED-MODALITY ,030204 cardiovascular system & hematology ,0302 clinical medicine ,INVOLVED-FIELD RADIOTHERAPY ,EUROPEAN ORGANIZATION ,Risk Factors ,Anthracyclines ,Survivors ,Randomized Controlled Trials as Topic ,Cumulative dose ,Hematology ,Middle Aged ,Hodgkin Disease ,CANCER ,COOPERATIVE GROUP ,3. Good health ,Cardiovascular Diseases ,030220 oncology & carcinogenesis ,Female ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] ,medicine.drug ,Adult ,Vincristine ,medicine.medical_specialty ,HEART-DISEASE ,Radiation Dosage ,03 medical and health sciences ,Young Adult ,Internal medicine ,RADIATION-THERAPY ,medicine ,Humans ,Vinca Alkaloids ,Aged ,Retrospective Studies ,Cardiotoxicity ,Radiotherapy ,business.industry ,Retrospective cohort study ,medicine.disease ,Hodgkin's lymphoma ,Surgery ,IRRADIATION ,Radiation therapy ,MYOCARDIAL-INFARCTION ,CLINICAL STAGE-I ,Heart failure ,Human medicine ,business - Abstract
Item does not contain fulltext BACKGROUND: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma. METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004. We reconstructed the mean radiation doses to the heart and carotid arteries and the cumulative doses of anthracyclines and vinca-alkaloids for all patients. Incidence of cardiovascular disease was reported during follow-up and updated through the LSQ. We applied Cox proportional hazards regression analyses to quantify the effect of chemotherapy and radiation on the risk of a first cardiovascular disease event. FINDINGS: Information of primary treatment was complete for 6039 patients (median age at diagnosis 30 years [IQR 23-40]; median length of follow-up 9 years [6-14]). 1919 patients responded to the LSQ. 1238 first cardiovascular events were recorded in 703 patients, most were ischaemic heart disease (132 [19%]), congestive heart failure (85 [12%]), arrhythmia (110 [16%]), and valvular disease (77 [11%]). The mean heart radiation dose per 1 Gy increase (HR 1.015 [95% CI 1.006-1.024], p=0.0014) and the dose of anthracyclines per 50 mg/m(2) increase in cumulative dose (1.077 [1.021-1.137], p=0.0064) were significant predictors of cardiovascular disease. Cumulative dose of vinblastine (unadjusted model p=0.77), vincristine (p=0.36), and mean radiation dose to the left (p=0.41) or right (p=0.70) internal carotid artery did not predict for cardiovascular events. INTERPRETATION: Quantification of the increased cardiovascular risk with specific doses of radiation and anthracycline exposure will enable a quantitative assessment of the optimum combination of systemic therapy and radiation, which will help clinicians to balance the risks and benefits of different regimens for individual patients. FUNDING: Rigshospitalet Research Committee, the EORTC Cancer Research Fund, and the Sally Snowman Survivorship Fellowship.
- Published
- 2015
4. PRELIMINARY RESULTS OF A QUALITY CONTROL STUDY ON INVOLVED NODE RADIOTHERAPY IN THE EORTC/LYSA/FIL H10 TRIAL ON STAGES I/II HODGKIN LYMPHOMA
- Author
-
Aleman, B.M., primary, Ricardi, U., additional, van der Maazen, R.W., additional, Meijnders, P., additional, Beijert, M., additional, Boros, A., additional, Izar, F., additional, Janus, C.P., additional, Levis, M., additional, Martin, V., additional, Specht, L., additional, Corning, C., additional, Clementel, E., additional, Fortpied, C., additional, Raemaekers, J.M., additional, Andre, M.P., additional, Federico, M., additional, and Girinsky, T., additional
- Published
- 2019
- Full Text
- View/download PDF
5. Risk of diabetes after para-aortic radiation for testicular cancer
- Author
-
Groot, Harmke J., Gietema, J.A., Aleman, B.M., Incrocci, L., Wit, R. de, Witjes, J.A., Leeuwen, F.E. van, Schaapveld, M., Groot, Harmke J., Gietema, J.A., Aleman, B.M., Incrocci, L., Wit, R. de, Witjes, J.A., Leeuwen, F.E. van, and Schaapveld, M.
- Abstract
Contains fulltext : 198213.pdf (Publisher’s version ) (Open Access)
- Published
- 2018
6. Controversies and consensus in the diagnosis, work-up and treatment of gastric lymphoma: An international survey
- Author
-
de Jong, D., Aleman, B.M. P., Taal, B.G., and Boot, H.
- Published
- 1999
- Full Text
- View/download PDF
7. Infradiaphragmatic irradiation and high procarbazine doses increase colorectal cancer risk in Hodgkin lymphoma survivors
- Author
-
Eggermond, A.M. van, Schaapveld, M., Janus, C.P., Boer, J.P. de, Krol, A.D., Zijlstra, J.M., Maazen, R.W.M. van der, Kremer, L.C., Leerdam, M.E. van, Louwman, M.W., Visser, O, Bruin, M.L. De, Aleman, B.M., Leeuwen, F.E. van, Eggermond, A.M. van, Schaapveld, M., Janus, C.P., Boer, J.P. de, Krol, A.D., Zijlstra, J.M., Maazen, R.W.M. van der, Kremer, L.C., Leerdam, M.E. van, Louwman, M.W., Visser, O, Bruin, M.L. De, Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 177780.pdf (Publisher’s version ) (Open Access), BACKGROUND: Hodgkin lymphoma (HL) survivors are at increased risk of second malignancies, but few studies have assessed colorectal cancer (CRC) risk after HL treatment. We assessed long-term, subsite-specific CRC risk associated with specific radiation fields and chemotherapy regimens. METHODS: In a Dutch cohort of 3121 5-year HL survivors treated between 1965 and 1995, subsite-specific CRC incidence was compared with general population rates. Treatment effects were quantified by Cox regression analyses. RESULTS: After a median follow-up of 22.9 years, 55 patients developed CRC. The standardized incidence ratios (SIR) was 2.4-fold increased (95% confidence interval (95%CI) 1.8-3.2), leading to 5.7 excess cases per 10 000 patient-years. Risk was still increased 30 years after HL treatment (SIR: 2.8; 95%CI: 1.6-4.6). The highest (SIR: 6.5, 95%CI: 3.3-11.3) was seen for transverse colon cancer (15.0 (95%CI: 4.3-40.8) after inverted-Y irradiation). A prescribed cumulative procarbazine dose >4.2 g m-2 was associated with a 3.3-fold higher CRC risk (95%CI: 1.8-6.1) compared to treatment without procarbazine. Patients receiving >4.2 g m-2 procarbazine and infradiaphragmatic radiotherapy had a hazard ratio of 6.8 (95%CI: 3.0-15.6) compared with patients receiving neither treatment, which is significantly higher than an additive joint effect (Padditivity=0.004). CONCLUSIONS: Colorectal cancer surveillance should be considered for HL survivors who received Infradiaphragmatic radiotherapy and a high cumulative procarbazine dose.
- Published
- 2017
8. Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design
- Author
-
Rigter, L.S., Spaander, M.C., Moons, L.M., Bisseling, T.M., Aleman, B.M., Boer, J.P. de, Lugtenburg, P.J., Janus, C.P., Petersen, E.J., Roesink, J.M., Raemaekers, J.M.M., Maazen, R.W.M. van der, Cats, A., Bleiker, E.M., Snaebjornsson, P., Carvalho, B., Lansdorp-Vogelaar, I., Jozwiak, K., Riele, H. Te, Meijer, G.A., Leeuwen, F.E. van, Leerdam, M.E. van, Rigter, L.S., Spaander, M.C., Moons, L.M., Bisseling, T.M., Aleman, B.M., Boer, J.P. de, Lugtenburg, P.J., Janus, C.P., Petersen, E.J., Roesink, J.M., Raemaekers, J.M.M., Maazen, R.W.M. van der, Cats, A., Bleiker, E.M., Snaebjornsson, P., Carvalho, B., Lansdorp-Vogelaar, I., Jozwiak, K., Riele, H. Te, Meijer, G.A., Leeuwen, F.E. van, and Leerdam, M.E. van
- Abstract
Contains fulltext : 169927.pdf (publisher's version ) (Open Access), BACKGROUND: Second primary malignancies are a major cause of excess morbidity and mortality in cancer survivors. Hodgkin lymphoma survivors who were treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine have an increased risk to develop colorectal cancer. Colonoscopy surveillance plays an important role in colorectal cancer prevention by removal of the precursor lesions (adenomas) and early detection of cancer, resulting in improved survival rates. Therefore, Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy and/or high-dose procarbazine could benefit from colonoscopy, or other surveillance modalities, which are expected to reduce colorectal cancer incidence and mortality. Current knowledge on clinicopathological and molecular characteristics of therapy-related colorectal cancer is limited. The pathogenesis of such colorectal cancers might be different from the pathogenesis in the general population and therefore these patients might require a different clinical approach. We designed a study with the primary aim to assess the diagnostic yield of a first surveillance colonoscopy among Hodgkin lymphoma survivors at increased risk of colorectal cancer and to compare these results with different screening modalities in the general population. Secondary aims include assessment of the test characteristics of stool tests and evaluation of burden, acceptance and satisfaction of CRC surveillance through two questionnaires. METHODS/DESIGN: This prospective multicenter cohort study will include Hodgkin lymphoma survivors who survived >/=8 years after treatment with infradiaphragmatic radiotherapy and/or procarbazine (planned inclusion of 259 participants). Study procedures will consist of a surveillance colonoscopy with removal of precursor lesions (adenomas) and 6-8 normal colonic tissue biopsies, a fecal immunochemical test and a stool DNA test. All neoplastic lesions encountered will be classified using relevant histomorphological
- Published
- 2017
9. Attendance to HODGKIN lymphoma survivorship care clinics in the Netherlands
- Author
-
Aleman, B.M., primary, Nijdam, A., additional, van 't Veer, M.B., additional, Janus, C.P., additional, de Weijer, R.J., additional, Petersen, E.J., additional, Roesink, J., additional, Zijlstra, J.M., additional, Lugtenburg, P.J., additional, van der Maazen, R.W., additional, Raemaekers, J.M., additional, and van Leeuwen, F.E., additional
- Published
- 2017
- Full Text
- View/download PDF
10. COMBINED RISK OF SECOND MALIGNANT NEOPLASMS AND CARDIOVASCULAR DISEASE IN LONG-TERM HODGKIN LYMPHOMA SURVIVORS
- Author
-
Aleman, B.M., primary, de Vries, S., additional, van Nimwegen, F.A., additional, Schaapveld, M., additional, Lugtenburg, P.J., additional, Krol, A.D., additional, Roesink, J., additional, Raemaekers, J.M., additional, and van Leeuwen, F.E., additional
- Published
- 2017
- Full Text
- View/download PDF
11. [The BETER survivorship care initiative for Hodgkin lymphoma; tailored survivorship care for late effects of treatment]
- Author
-
Dekker, N., Veer, M.B. van 't, Aleman, B.M., Leeuwen, F.E. van, and Raemaekers, J.M.M.
- Subjects
humanities ,Rare cancers Radboud Institute for Health Sciences [Radboudumc 9] - Abstract
Item does not contain fulltext The Dutch BETER consortium has established a national care infrastructure for Hodgkin lymphoma survivors. 'BETER' [the Dutch word for 'better'] stands for Better care after Hodgkin lymphoma (HL): Evaluation of long-term Treatment Effects and screening Recommendations. The survivorship care focuses on long-term effects of HL treatment. Over 10,000 HL survivors who were treated in the period spanning 1965-2008 have been identified. As part of the survivorship care initiative, specific BETER out-patient clinics have been set up. A dedicated website, www.beternahodgkin.nl, provides HL survivors with relevant information. The stakeholders of the BETER survivorship care programme aim to achieve an improved healthy life expectancy for patients treated for HL.
- Published
- 2015
12. Radiation Dose-Response Relationship for Risk of Coronary Heart Disease in Survivors of Hodgkin Lymphoma
- Author
-
Nimwegen, F.A. van, Schaapveld, M., Cutter, D.J., Janus, C.P., Krol, A.D., Hauptmann, M., Kooijman, K., Roesink, J.M., Maazen, R.W.M. van der, Darby, S.C., Aleman, B.M., Leeuwen, F.E. van, Nimwegen, F.A. van, Schaapveld, M., Cutter, D.J., Janus, C.P., Krol, A.D., Hauptmann, M., Kooijman, K., Roesink, J.M., Maazen, R.W.M. van der, Darby, S.C., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 165755.pdf (publisher's version ) (Open Access), PURPOSE: Cardiovascular diseases are increasingly recognized as late effects of Hodgkin lymphoma (HL) treatment. The purpose of this study was to identify the risk factors for coronary heart disease (CHD) and to quantify the effects of radiation dose to the heart, chemotherapy, and other cardiovascular risk factors. PATIENTS AND METHODS: We conducted a nested case-control study in a cohort of 2,617 5-year HL survivors, treated between 1965 and 1995. Cases were patients diagnosed with CHD as their first cardiovascular event after HL. Detailed treatment information was collected from medical records of 325 cases and 1,204 matched controls. Radiation charts and simulation radiographs were used to estimate in-field heart volume and mean heart dose (MHD). A risk factor questionnaire was sent to patients still alive. RESULTS: The median interval between HL and CHD was 19.0 years. Risk of CHD increased linearly with increasing MHD (excess relative risk [ERR]) per Gray, 7.4%; 95% CI, 3.3% to 14.8%). This results in a 2.5-fold increased risk of CHD for patients receiving a MHD of 20 Gy from mediastinal radiotherapy, compared with patients not treated with mediastinal radiotherapy. ERRs seemed to decrease with each tertile of age at treatment (ERR/Gy(<27.5years), 20.0%; ERR/Gy(27.5-36.4years), 8.8%; ERR/Gy(36.5-50.9years), 4.2%; P(interaction) = .149). Having >/= 1 classic CHD risk factor (diabetes mellitus, hypertension, or hypercholesterolemia) independently increased CHD risk (rate ratio, 1.5; 95% CI, 1.1 to 2.1). A high level of physical activity was associated with decreased CHD risk (rate ratio, 0.5; 95% CI, 0.3 to 0.8). CONCLUSION: The linear radiation dose-response relationship identified can be used to predict CHD risk for future HL patients and survivors. Appropriate early management of CHD risk factors and stimulation of physical activity may reduce CHD risk in HL survivors.
- Published
- 2016
13. Cardiovascular Disease Risk in a Large, Population-Based Cohort of Breast Cancer Survivors
- Author
-
Boekel, N.B., Schaapveld, M., Gietema, J.A., Russell, N.S., Poortmans, P., Theuws, J.C., Schinagl, D.A., Rietveld, D.H., Versteegh, M.I., Visser, O, Rutgers, E.J., Aleman, B.M., Leeuwen, F.E. van, Boekel, N.B., Schaapveld, M., Gietema, J.A., Russell, N.S., Poortmans, P., Theuws, J.C., Schinagl, D.A., Rietveld, D.H., Versteegh, M.I., Visser, O, Rutgers, E.J., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Item does not contain fulltext, PURPOSE: To conduct a large, population-based study on cardiovascular disease (CVD) in breast cancer (BC) survivors treated in 1989 or later. METHODS AND MATERIALS: A large, population-based cohort comprising 70,230 surgically treated stage I to III BC patients diagnosed before age 75 years between 1989 and 2005 was linked with population-based registries for CVD. Cardiovascular disease risks were compared with the general population, and within the cohort using competing risk analyses. RESULTS: Compared with the general Dutch population, BC patients had a slightly lower CVD mortality risk (standardized mortality ratio 0.92, 95% confidence interval [CI] 0.88-0.97). Only death due to valvular heart disease was more frequent (standardized mortality ratio 1.28, 95% CI 1.08-1.52). Left-sided radiation therapy after mastectomy increased the risk of any cardiovascular event compared with both surgery alone (subdistribution hazard ratio (sHR) 1.23, 95% CI 1.11-1.36) and right-sided radiation therapy (sHR 1.19, 95% CI 1.04-1.36). Radiation-associated risks were found for not only ischemic heart disease, but also for valvular heart disease and congestive heart failure (CHF). Risks were more pronounced in patients aged <50 years at BC diagnosis (sHR 1.48, 95% CI 1.07-2.04 for left- vs right-sided radiation therapy after mastectomy). Left- versus right-sided radiation therapy after wide local excision did not increase the risk of all CVD combined, yet an increased ischemic heart disease risk was found (sHR 1.14, 95% CI 1.01-1.28). Analyses including detailed radiation therapy information showed an increased CVD risk for left-sided chest wall irradiation alone, left-sided breast irradiation alone, and internal mammary chain field irradiation, all compared with right-sided breast irradiation alone. Compared with patients not treated with chemotherapy, chemotherapy used >/=1997 (ie, anthracyline-based chemotherapy) increased the risk of CHF (sHR 1.35, 95% CI 1.00-1.83). CONCLUSIO
- Published
- 2016
14. PO-0709: Interobserver variation of CT and FDG-PET based GTV for oesophageal cancer: a Dutch nationwide study
- Author
-
Nowee, M.E., primary, Voncken, F.E., additional, Kotte, A.N., additional, Goense, L., additional, Van Rossum, P.S.N., additional, Van Lier, A.L.H.M.W., additional, Aleman, B.M., additional, Van Vulpen, M., additional, Meijer, G.J., additional, and Lips, I.M., additional
- Published
- 2016
- Full Text
- View/download PDF
15. Cardiovascular disease after treatment for Hodgkin's lymphoma: an analysis of nine collaborative EORTC-LYSA trials
- Author
-
Maraldo, M.V., Giusti, F., Vogelius, I.R., Lundemann, M., Kaaij, M.A. van der, Ramadan, S., Meulemans, B., Henry-Amar, M., Aleman, B.M., Raemaekers, J.M.M., Meijnders, P., Moser, E.C., Kluin-Nelemans, H.C., Feugier, P., Casasnovas, O., Fortpied, C., Specht, L., et al., Maraldo, M.V., Giusti, F., Vogelius, I.R., Lundemann, M., Kaaij, M.A. van der, Ramadan, S., Meulemans, B., Henry-Amar, M., Aleman, B.M., Raemaekers, J.M.M., Meijnders, P., Moser, E.C., Kluin-Nelemans, H.C., Feugier, P., Casasnovas, O., Fortpied, C., Specht, L., and et al.
- Abstract
Item does not contain fulltext, BACKGROUND: Cardiovascular disease after treatment is an important concern in cancer survivors. However, knowledge of cardiotoxicity is limited by the retrospective nature of data, which often does not contain details of treatment exposure. To facilitate individual risk counselling of patients, we aimed to quantify the effect of anthracyclines, vinca-alkaloids, and radiotherapy on the risk of cardiovascular disease in patients treated for Hodgkin's lymphoma. METHODS: In 2009-10, a Life Situation Questionnaire (LSQ) was distributed to patients by mail to assess late-onset effects of Hodgkin's lymphoma treatment in patients who were included in nine successive European Organisation for Research and Treatment of Cancer (EORTC) and the Groupe d'Etude des Lymphomes de l'Adulte (GELA, now renamed LYSA) randomised trials between 1964 and 2004. We reconstructed the mean radiation doses to the heart and carotid arteries and the cumulative doses of anthracyclines and vinca-alkaloids for all patients. Incidence of cardiovascular disease was reported during follow-up and updated through the LSQ. We applied Cox proportional hazards regression analyses to quantify the effect of chemotherapy and radiation on the risk of a first cardiovascular disease event. FINDINGS: Information of primary treatment was complete for 6039 patients (median age at diagnosis 30 years [IQR 23-40]; median length of follow-up 9 years [6-14]). 1919 patients responded to the LSQ. 1238 first cardiovascular events were recorded in 703 patients, most were ischaemic heart disease (132 [19%]), congestive heart failure (85 [12%]), arrhythmia (110 [16%]), and valvular disease (77 [11%]). The mean heart radiation dose per 1 Gy increase (HR 1.015 [95% CI 1.006-1.024], p=0.0014) and the dose of anthracyclines per 50 mg/m(2) increase in cumulative dose (1.077 [1.021-1.137], p=0.0064) were significant predictors of cardiovascular disease. Cumulative dose of vinblastine (unadjusted model p=0.77), vincristine (p=0.36)
- Published
- 2015
16. Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk
- Author
-
Nimwegen, F.A. van, Schaapveld, M., Janus, C.P., Krol, A.D., Petersen, E.J., Raemaekers, J.M.M., Kok, W.E., Aleman, B.M., Leeuwen, F.E. van, Nimwegen, F.A. van, Schaapveld, M., Janus, C.P., Krol, A.D., Petersen, E.J., Raemaekers, J.M.M., Kok, W.E., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Item does not contain fulltext, IMPORTANCE: Hodgkin lymphoma (HL) survivors are at increased risk of cardiovascular diseases. It is unclear, however, how long the increased risk persists and what the risk factors are for various cardiovascular diseases. OBJECTIVES: To examine relative and absolute excess risk up to 40 years since HL treatment compared with cardiovascular disease incidence in the general population and to study treatment-related risk factors for different cardiovascular diseases. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 2524 Dutch patients diagnosed as having HL at younger than 51 years (median age, 27.3 years) who had been treated from January 1, 1965, through December 31, 1995, and had survived for 5 years since their diagnosis. EXPOSURES: Treatment for HL, including prescribed mediastinal radiotherapy dose and anthracycline dose. MAIN OUTCOMES AND MEASURES: Data were collected from medical records and general practitioners. Cardiovascular events, including coronary heart disease (CHD), valvular heart disease (VHD), and cardiomyopathy and congestive heart failure (HF), were graded according to the Common Terminology Criteria for Adverse Events, version 4.0. RESULTS: After a median follow-up of 20 years, we identified 1713 cardiovascular events in 797 patients. After 35 years or more, patients still had a 4- to 6-fold increased standardized incidence ratio of CHD or HF compared with the general population, corresponding to 857 excess events per 10,000 person-years. Highest relative risks were seen in patients treated before 25 years of age, but substantial absolute excess risks were also observed for patients treated at older ages. Within the cohort, the 40-year cumulative incidence of cardiovascular diseases was 50% (95% CI, 47%-52%). Fifty-one percent of patients with a cardiovascular disease developed multiple events. For patients treated before 25 years of age, cumulative incidences at 60 years or older were 20%, 31%, and 11% for CHD, VHD, an
- Published
- 2015
17. Second Cancer Risk Up to 40 Years after Treatment for Hodgkin's Lymphoma
- Author
-
Schaapveld, M., Aleman, B.M., Eggermond, A.M. van, Janus, C.P., Krol, A.D., Maazen, R.W.M. van der, Roesink, J.M., Raemaekers, J.M.M., Boer, J.P. de, Zijlstra, J.M., Imhoff, G.W. van, Petersen, E.J., Poortmans, P.M.P., Beijert, M., Lybeert, M.L., Mulder, I., Visser, O, Louwman, M.W., Krul, I.M., Lugtenburg, P.J., Leeuwen, F.E. van, Schaapveld, M., Aleman, B.M., Eggermond, A.M. van, Janus, C.P., Krol, A.D., Maazen, R.W.M. van der, Roesink, J.M., Raemaekers, J.M.M., Boer, J.P. de, Zijlstra, J.M., Imhoff, G.W. van, Petersen, E.J., Poortmans, P.M.P., Beijert, M., Lybeert, M.L., Mulder, I., Visser, O, Louwman, M.W., Krul, I.M., Lugtenburg, P.J., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 152700.pdf (publisher's version ) (Open Access), BACKGROUND: Survivors of Hodgkin's lymphoma are at increased risk for treatment-related subsequent malignant neoplasms. The effect of less toxic treatments, introduced in the late 1980s, on the long-term risk of a second cancer remains unknown. METHODS: We enrolled 3905 persons in the Netherlands who had survived for at least 5 years after the initiation of treatment for Hodgkin's lymphoma. Patients had received treatment between 1965 and 2000, when they were 15 to 50 years of age. We compared the risk of a second cancer among these patients with the risk that was expected on the basis of cancer incidence in the general population. Treatment-specific risks were compared within the cohort. RESULTS: With a median follow-up of 19.1 years, 1055 second cancers were diagnosed in 908 patients, resulting in a standardized incidence ratio (SIR) of 4.6 (95% confidence interval [CI], 4.3 to 4.9) in the study cohort as compared with the general population. The risk was still elevated 35 years or more after treatment (SIR, 3.9; 95% CI, 2.8 to 5.4), and the cumulative incidence of a second cancer in the study cohort at 40 years was 48.5% (95% CI, 45.4 to 51.5). The cumulative incidence of second solid cancers did not differ according to study period (1965-1976, 1977-1988, or 1989-2000) (P=0.71 for heterogeneity). Although the risk of breast cancer was lower among patients who were treated with supradiaphragmatic-field radiotherapy not including the axilla than among those who were exposed to mantle-field irradiation (hazard ratio, 0.37; 95% CI, 0.19 to 0.72), the risk of breast cancer was not lower among patients treated in the 1989-2000 study period than among those treated in the two earlier periods. A cumulative procarbazine dose of 4.3 g or more per square meter of body-surface area (which has been associated with premature menopause) was associated with a significantly lower risk of breast cancer (hazard ratio for the comparison with no chemotherapy, 0.57; 95% CI, 0.39 to 0.
- Published
- 2015
18. Second cancer risk 40 years after cure for Hodgkin lymphoma
- Author
-
Schaapveld, M., Aleman, B.M., Eggermond, A.M., Janus, C.P., Krol, A., Maazen, R.W.M. van der, Raemaekers, J.M.M., Boer, J.P. de, Zijlstra, J.M., Imhoff, G.W. van, Beijert, M.L., Poortmans, P.M., Lybeert, M.L., Mulder, I., Visser, O., Louwman, M.J., Sombroek, C., Lugtenburg, P., and Leeuwen, F.E. van
- Published
- 2012
19. OC-0268: A Dutch nationwide survivorship care programme for (non-) Hodgkin lymphoma survivors
- Author
-
Dekker, N., primary, Van Leeuwen, F.E., additional, Van 't Veer, M.B., additional, Janus, C.P., additional, Krol, A.D., additional, Van der Maazen, R.W., additional, Van Imhoff, G.W., additional, Zijlstra, J.M., additional, Ong, F., additional, Borger, J., additional, Roesink, J.M., additional, Poortmans, P.E., additional, Kersten, M.J., additional, Vos-Westerman, J., additional, Lybeert, M.L., additional, Schimmel, E., additional, Rutten, E., additional, Schippers, M., additional, Kusumanto, Y., additional, Smit, W.G., additional, Muller, K., additional, Van Kampen, E., additional, Raemaekers, J.M., additional, and Aleman, B.M., additional
- Published
- 2015
- Full Text
- View/download PDF
20. Risk of multiple primary malignancies following treatment of Hodgkin lymphoma
- Author
-
Eggermond, A.M. van, Schaapveld, M., Lugtenburg, P.J., Krol, A.D., Boer, J.P. de, Zijlstra, J.M., Raemaekers, J.M.M., Kremer, L.C., Roesink, J.M., Louwman, M.W., Aleman, B.M., Leeuwen, F.E. van, Eggermond, A.M. van, Schaapveld, M., Lugtenburg, P.J., Krol, A.D., Boer, J.P. de, Zijlstra, J.M., Raemaekers, J.M.M., Kremer, L.C., Roesink, J.M., Louwman, M.W., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 137565.pdf (publisher's version ) (Closed access), We assessed risk, localization, and timing of third malignancies in Hodgkin lymphoma (HL) survivors. In a cohort of 3122 5-year HL survivors diagnosed before the age of 51 years and treated between 1965 and 1995, we examined whether risk factors for second and third malignancies differ and whether the occurrence of a second malignancy affects the risk of subsequent malignancies, using recurrent event analyses. After a median follow-up of 22.6 years, 832 patients developed a second malignancy and 126 patients a third one. The risk of a second malignancy was 4.7-fold increased (95% confidence interval [CI], 4.4-5.1) compared with risk in the general population; the risk for a third malignancy after a second malignancy was 5.4-fold (95% CI, 4.4-6.5) increased. The 10-year cumulative incidence of any third malignancy was 13.3%. Compared with patients still free of a second malignancy, patients with a second malignancy had a higher risk of developing subsequent malignancies. This risk depended on age, with hazard ratios of 2.2, 1.6, and 1.1 for patients aged <25, 25 to 34, and 35 to 50 years at HL treatment, respectively. In HL survivors who had a second malignancy, treating physicians should be aware of the increased risk of subsequent malignancies.
- Published
- 2014
21. Risk of diabetes mellitus in long-term survivors of Hodgkin lymphoma
- Author
-
Nimwegen, F.A. van, Schaapveld, M., Janus, C.P., Krol, A.D., Raemaekers, J.M.M., Kremer, L.C., Stovall, M., Aleman, B.M., Leeuwen, F.E. van, Nimwegen, F.A. van, Schaapveld, M., Janus, C.P., Krol, A.D., Raemaekers, J.M.M., Kremer, L.C., Stovall, M., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Item does not contain fulltext, PURPOSE: Recently, an increased risk of diabetes mellitus (DM) was observed after abdominal irradiation for childhood cancer. Because many Hodgkin lymphoma (HL) survivors have also been treated with infradiaphragmatic radiotherapy, we evaluated the association between HL treatment and DM risk. PATIENTS AND METHODS: Our study cohort comprised 2,264 5-year HL survivors, diagnosed before age 51 years and treated between 1965 and 1995. Treatment and follow-up information was collected from medical records and general practitioners. Radiation dosimetry was performed to estimate radiation dose to the pancreas. Cumulative incidence of DM was estimated, and risk factors for DM were evaluated by using Cox regression. RESULTS: After a median follow-up of 21.5 years, 157 patients developed DM. Overall cumulative incidence of DM after 30 years was 8.3% (95% CI, 6.9% to 9.8%). After para-aortic radiation with >/= 36 Gy, the 30-year cumulative incidence of DM was 14.2% (95% CI, 10.7% to 18.3%). Irradiation with >/= 36 Gy to the para-aortic lymph nodes and spleen was associated with a 2.30-fold increased risk of DM (95% CI, 1.54- to 3.44-fold) whereas para-aortic radiation alone with >/= 36 Gy was associated with a 1.82-fold increased risk (95% CI, 1.02- to 3.25-fold). Lower doses (10 to 35 Gy) did not significantly increase risk of DM. The risk of DM significantly increased with higher mean radiation doses to the pancreatic tail (P < .001). CONCLUSION: Radiation to the para-aortic lymph nodes increases the risk of developing DM in 5-year HL survivors. Screening for DM should be considered in follow-up guidelines for HL survivors, and treating physicians should be alert to this increased risk.
- Published
- 2014
22. Cryopreservation, semen use and the likelihood of fatherhood in male Hodgkin lymphoma survivors: an EORTC-GELA Lymphoma Group cohort study
- Author
-
Kaaij, M.A. van der, Echten-Arends, J. van, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L., Casasnovas, O., Andre, M., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., et al., Kaaij, M.A. van der, Echten-Arends, J. van, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Eghbali, H., Brice, P., Smit, W.G., Sebban, C., Doorduijn, J.K., Roesink, J.M., Gaillard, I., Coiffier, B., Lybeert, M.L., Casasnovas, O., Andre, M., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, J.C., and et al.
- Abstract
Contains fulltext : 137720.pdf (publisher's version ) (Closed access), STUDY QUESTION: How does the successful cryopreservation of semen affect the odds of post-treatment fatherhood among Hodgkin lymphoma (HL) survivors? SUMMARY ANSWER: Among 334 survivors who wanted to have children, the availability of cryopreserved semen doubled the odds of post-treatment fatherhood. WHAT IS KNOWN ALREADY: Cryopreservation of semen is the easiest, safest and most accessible way to safeguard fertility in male patients facing cancer treatment. Little is known about what proportion of patients achieve successful semen cryopreservation. To our knowledge, neither the factors which influence the occurrence of semen cryopreservation nor the rates of fatherhood after semen has been cryopreserved have been analysed before. STUDY DESIGN, SIZE, DURATION: This is a cohort study with nested case-control analyses of consecutive Hodgkin survivors treated between 1974 and 2004 in multi-centre randomized controlled trials. A written questionnaire was developed and sent to 1849 male survivors. PARTICIPANTS/MATERIALS, SETTING, METHODS: Nine hundred and two survivors provided analysable answers. The median age at treatment was 31 years. The median follow-up after cryopreservation was 13 years (range 5-36). MAIN RESULTS AND THE ROLE OF CHANCE: Three hundred and sixty-three out of 902 men (40%) cryopreserved semen before the start of potentially gonadotoxic treatment. The likelihood of semen cryopreservation was influenced by age, treatment period, disease stage, treatment modality and education level. Seventy eight of 363 men (21%) used their cryopreserved semen. Men treated between 1994 and 2004 had significantly lower odds of cryopreserved semen use compared with those treated earlier, whereas alkylating or second-line (chemo)therapy significantly increased the odds of use; no other influencing factors were identified. We found an adjusted odds ratio of 2.03 (95% confidence interval 1.11-3.73, P = 0.02) for post-treatment fatherhood if semen cryopreservation was perfo
- Published
- 2014
23. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.
- Author
-
Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Bologna, S., Ong, F., Eghbali, H., Doorduijn, J.K., Morschhauser, F., Sebban, C., Roesink, J.M., Bouteloup, M., Hoof, A. van, Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, H.C., Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, E.C., Allgeier, A., Meulemans, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Bologna, S., Ong, F., Eghbali, H., Doorduijn, J.K., Morschhauser, F., Sebban, C., Roesink, J.M., Bouteloup, M., Hoof, A. van, Raemaekers, J.M.M., Henry-Amar, M., and Kluin-Nelemans, H.C.
- Abstract
Contains fulltext : 109132.pdf (publisher's version ) (Open Access), PURPOSE: In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment. PATIENTS AND METHODS: The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Etude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis. RESULTS: Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF. CONCLUSION: Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.
- Published
- 2012
24. Parenthood in survivors of Hodgkin lymphoma: an EORTC-GELA general population case-control study.
- Author
-
Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, L.C., Allgeier, A., Meulemans, B., Dubois, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Doorduijn, J.K., Sebban, C., Smit, W.G., Bologna, S., Roesink, J.M., Ong, F., Andre, M.P., Raemaekers, J.M.M., Henry-Amar, M., Kluin-Nelemans, H.C., Kaaij, M.A. van der, Heutte, N., Meijnders, P., Abeilard-Lemoisson, E., Spina, M., Moser, L.C., Allgeier, A., Meulemans, B., Dubois, B., Simons, A.H., Lugtenburg, P.J., Aleman, B.M., Noordijk, E.M., Ferme, C., Thomas, J., Stamatoullas, A., Fruchart, C., Brice, P., Gaillard, I., Doorduijn, J.K., Sebban, C., Smit, W.G., Bologna, S., Roesink, J.M., Ong, F., Andre, M.P., Raemaekers, J.M.M., Henry-Amar, M., and Kluin-Nelemans, H.C.
- Abstract
Contains fulltext : 108966.pdf (publisher's version ) (Open Access), PURPOSE: We investigated the impact of Hodgkin lymphoma (HL) on parenthood, including factors influencing parenthood probability, by comparing long-term HL survivors with matched general population controls. PATIENTS AND METHODS: A Life Situation Questionnaire was sent to 3,604 survivors treated from 1964 to 2004 in successive clinical trials. Responders were matched with controls (1:3 or 4) for sex, country, education, and year of birth (10-year groups). Controls were given an artificial date of start of treatment equal to that of their matched case. The main end point was presence of biologic children after treatment, which was evaluated by using conditional logistic regression analysis. Logistic regression analysis was used to analyze factors influencing spontaneous post-treatment parenthood. RESULTS: In all, 1,654 French and Dutch survivors were matched with 6,414 controls. Median follow-up was 14 years (range, 5 to 44 years). After treatment, the odds ratio (OR) for having children was 0.77 (95% CI, 0.68 to 0.87; P < .001) for survivors compared with controls. Of 898 survivors who were childless before treatment, 46.7% achieved post-treatment parenthood compared with 49.3% of 3,196 childless controls (OR, 0.87; P = .08). Among 756 survivors with children before treatment, 12.4% became parents after HL treatment compared with 22.2% of 3,218 controls with children before treatment (OR, 0.49; P < .001). Treatment with alkylating agents, second-line therapy, and age older than 35 years at treatment appeared to reduce the chances of spontaneous post-treatment parenthood. CONCLUSION: Survivors of HL had slightly but significantly fewer children after treatment than matched general population controls. The difference concerned only survivors who had children before treatment and appears to have more personal than biologic reasons. The chance of successful post-treatment parenthood was 76%.
- Published
- 2012
25. Risk and prognostic significance of metachronous contralateral testicular germ cell tumours
- Author
-
Schaapveld, M., van den Belt-Dusebout, A.W., Gietema, J.A., de Wit, R., Horenblas, S., Witjes, J.A., Hoekstra, H.J., Kiemeney, L.A.L.M., Louwman, W.J., Ouwens, G.M., Aleman, B.M., van Leeuwen, F.E., Schaapveld, M., van den Belt-Dusebout, A.W., Gietema, J.A., de Wit, R., Horenblas, S., Witjes, J.A., Hoekstra, H.J., Kiemeney, L.A.L.M., Louwman, W.J., Ouwens, G.M., Aleman, B.M., and van Leeuwen, F.E.
- Abstract
Item does not contain fulltext, Background:Testicular germ cell tumour (TGCT) patients are at increased risk of developing a contralateral testicular germ cell tumour (CTGCT). It is unclear whether TGCT treatment affects CTGCT risk.Methods:The risk of developing a metachronous CTGCT (a CTGCT diagnosed >/=6 months after a primary TGCT) and its impact on patient's prognosis was assessed in a nationwide cohort comprising 3749 TGCT patients treated in the Netherlands during 1965-1995. Standardised incidence ratios (SIRs), comparing CTGCT incidence with TGCT incidence in the general population, and cumulative CTGCT incidence were estimated and CTGCT risk factors assessed, accounting for competing risks.Results:Median follow-up was 18.5 years. Seventy-seven metachronous CTGCTs were diagnosed. The SIR for metachronous CTGCTs was 17.6 (95% confidence interval (95% CI) 13.9-22.0). Standardised incidence ratios remained elevated for up to 20 years, while the 20-year cumulative incidence was 2.2% (95% CI 1.8-2.8%). Platinum-based chemotherapy was associated with a lower CTGCT risk among non-seminoma patients (hazard ratio 0.37, 95% CI 0.18-0.72). The CTGCT patients had a 2.3-fold (95% CI 1.3-4.1) increased risk to develop a subsequent non-TGCT cancer and, consequently, a 1.8-fold (95% CI 1.1-2.9) higher risk of death than patients without a CTGCT.Conclusion:The TGCT patients remain at increased risk of a CTGCT for up to 20 years. Treatment with platinum-based chemotherapy reduces this risk.
- Published
- 2012
26. Role of radiotherapy in the treatment of lymphomas of the gastrointestinal tract.
- Author
-
Aleman, B.M., Haas, R.L., Maazen, R.W.M. van der, Aleman, B.M., Haas, R.L., and Maazen, R.W.M. van der
- Abstract
1 februari 2010, Contains fulltext : 89355.pdf (publisher's version ) (Closed access), In patients with gastrointestinal lymphoma the most frequently involved site is the stomach (60%-75% of cases), followed by the small bowel, ileum, cecum, colon and rectum. The most common histological subtypes are extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT) and diffuse large B-cell lymphoma (DLBCL). The role of radiotherapy is most definite in early stage gastric lymphoma. The therapeutic approach for patients with gastric Non Hodgkin lymphoma (NHL) has changed significantly over the last decades. The primary treatment of limited gastric MALT lymphoma consists of Helicobacter pylori eradication. In case of insufficient response to H. pylori eradication or in case H. pylori is absent, irradiation of the stomach and perigastric lymph nodes to a dose of 30-40Gy in 15-20 fractions is indicated. In patients with gastric DLBCL conservative treatment with anthracycline-based chemotherapy alone or in combination with involved-field radiotherapy has become the therapy of choice.
- Published
- 2010
27. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma.
- Author
-
Bruin, M.L. De, Dorresteijn, L.D.A., Veer, M.B. van 't, Krol, A.D., Pal, H.J. van der, Kappelle, A.C., Boogerd, W., Aleman, B.M., Leeuwen, F.E. van, Bruin, M.L. De, Dorresteijn, L.D.A., Veer, M.B. van 't, Krol, A.D., Pal, H.J. van der, Kappelle, A.C., Boogerd, W., Aleman, B.M., and Leeuwen, F.E. van
- Abstract
Contains fulltext : 80232.pdf (publisher's version ) (Closed access), BACKGROUND: Information on clinically verified stroke and transient ischemic attack (TIA) following Hodgkin lymphoma is scarce. We quantified the long-term risk of cerebrovascular disease associated with the use of radiotherapy and chemotherapy in survivors of Hodgkin lymphoma and explored potential pathogenic mechanisms. METHODS: We performed a retrospective cohort study among 2201 five-year survivors of Hodgkin lymphoma treated before age 51 between 1965 and 1995. We compared incidence rates of clinically verified stroke and TIA with those in the general population. We used multivariable Cox regression techniques to study treatment-related factors and other risk factors. All statistical tests were two-sided. RESULTS: After a median follow-up of 17.5 years, 96 patients developed cerebrovascular disease (55 strokes, 31 TIAs, and 10 with both TIA and stroke; median age = 52 years). Most ischemic events were from large-artery atherosclerosis (36%) or cardioembolisms (24%). The standardized incidence ratio for stroke was 2.2 (95% confidence interval [CI] = 1.7 to 2.8), and for TIA, it was 3.1 (95% CI = 2.2 to 4.2). The risks remained elevated, compared with those in the general population, after prolonged follow-up. The cumulative incidence of ischemic stroke or TIA 30 years after Hodgkin lymphoma treatment was 7% (95% CI = 5% to 8%). Radiation to the neck and mediastinum was an independent risk factor for ischemic cerebrovascular disease (hazard ratio = 2.5, 95% CI = 1.1 to 5.6 vs without radiotherapy). Treatment with chemotherapy was not associated with an increased risk. Hypertension, diabetes mellitus, and hypercholesterolemia were associated with the occurrence of ischemic cerebrovascular disease, whereas smoking and overweight were not. CONCLUSIONS: Patients treated for Hodgkin lymphoma experience a substantially increased risk of stroke and TIA, associated with radiation to the neck and mediastinum. Physicians should consider appropriate risk-reducing strategies
- Published
- 2009
28. ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
- Author
-
Stewart, F.A., primary, Akleyev, A.V., additional, Hauer-Jensen, M., additional, Hendry, J.H., additional, Kleiman, N.J., additional, MacVittie, T.J., additional, Aleman, B.M., additional, Edgar, A.B., additional, Mabuchi, K., additional, Muirhead, C.R., additional, Shore, R.E., additional, and Wallace, W.H., additional
- Published
- 2012
- Full Text
- View/download PDF
29. Involved-field radiotherapy in patients with stage III/IV Hodgkin’s lymphoma: first results of the randomised EORTC trial # 20884
- Author
-
Aleman, B.M., primary, Raemaekers, J.M., additional, Henry-Amar, M., additional, Pinna, A., additional, Girinsky, T., additional, Lybeert, M.L., additional, Meerwaldt, J.H., additional, Thomas, J., additional, Tirelli, U., additional, and Mandard, A.M., additional
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.